FDA Enforcement Priorities Include Guidance On Detailing And Kickbacks
Executive Summary
FDA plans to weigh in on some of the pharmaceutical sales practices identified as problematic by the HHS Inspector General, FDA Commissioner McClellan indicated during an address to the National Press Club in Washington, D.C. Aug. 8
You may also be interested in...
FDA Strategic Plan: Outsourcing Reviews For One-Third Of FTEs By 2006
FDA expects to complete reviews of competitive outsourcing opportunities for certain accounting and clerical services by the end of fiscal year 2004
Bristol Pravachol Ads Broaden Indication, FDA Warning Letter Says
FDA is asking Bristol-Myers Squibb to correct Pravachol advertising claims that the agency says broadens the indication and patient populations for which the cholesterol-lowering agent is approved
Bristol Pravachol Ads Broaden Indication, FDA Warning Letter Says
FDA is asking Bristol-Myers Squibb to correct Pravachol advertising claims that the agency says broadens the indication and patient populations for which the cholesterol-lowering agent is approved